Toxoplasma Infection and Risk of Epilepsy: A Case-Control Study of Incident Patients Publisher Pubmed



Alizadeh Khatir A¹ ; Moghaddam SA² ; Almukhtar M³ ; Ghorbani H⁴ ; Babazadeh A⁵ ; Mehravar S⁶ ; Rostami A⁵ Show Affiliations
Source: Microbial Pathogenesis Published:2021

Abstract

We performed an age matched case-control study of incident epileptic patients to assess the relationship between Toxoplasma gondii seropositivity and epilepsy. Cases were 94 newly diagnosed patients (mean age, 36.7 ± 15.9) with unprovoked convulsive epilepsy of unknown etiology and controls were 88 healthy individuals (mean age, 37.5 ± 17.1) with no history of epilepsy or neurological disorders. Sera of all subjects were examined for anti-Toxoplasma IgG antibodies using commercially enzyme-linked immunoassays. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) using univariate analysis and logistic regression, adjusted for potential confounders. The prevalence of anti-Toxoplasma IgG antibodies in epileptic patients (68.1%; 95%CI, 57.6–77.3%) was significantly higher than healthy controls (47.7%; 95%CI, 36.9–58.6%), indicating a significant relationship between Toxoplasma infection seropositivity and epilepsy (adjusted OR, 2.58; 95%CI, 1.16–5.72; P value < 0.05). The univariate analyses showed more than two-fold higher Toxoplasma seropositivity in patients with focal (OR, 2.31; 95%CI, 0.94–5.67) and generalized (OR, 2.35; 95%CI, 1.215–4.57) seizures versus healthy controls. Our findings support hypothesis that Toxoplasma infection/exposure may play an important role in development of epilepsy. Preventive measures to control of Toxoplasma infection especially in north of Iran and early treatment might be effective to reduce the occurrence of epilepsy in this region. © 2021 Elsevier Ltd